alexa Early Secondary Cytoreduction May Be Associated With Better Surgical Outcomes In Recurrent Epithelial Ovarian Cancer
ISSN: 2161-0932

Gynecology & Obstetrics
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

3rd Annual Conference on Gynecologic Oncology & Preventive Oncology
July 20-21, 2017 Chicago, USA

Nabeela Shami
Lahore Medical & Dental College, Pakistan
ScientificTracks Abstracts: Gynecol Obstet (Sunnyvale)
DOI: 10.4172/2161-0932-C1-015
Abstract
Background & Aim: Secondary cytoreductive surgery should be considered in all patients with recurrent epithelial ovarian cancer as optimal secondary cytoreduction has been associated with improved survival, irrespective of duration of disease free interval (DFI). A good performance status, initial optimal cytoreduction and absence of ascities are suggestive of increased odds of optimal secondary cytoreduction. Extent of disease is also a major determinant as patients with smaller disease burden are more likely to achieve optimal cytoreduction. Consequently, delay in secondary cytoreduction may reduce the number of patients who can undergo optimal cytoreduction. As yet, there is no consensus in literature regarding the optimum timing of secondary cytoreduction in patients with recurrent disease. The present series aims to document the success rate of optimal secondary cytoreduction in patients based on their DFI. Methods: Patients who had undergone primary cytoreductive surgery had received chemotherapy and showed a complete response but subsequently presented with disease recurrence were included. Evidence of measurable disease on imaging study was required. Abdomen was opened with a vertical incision, ascitic fluid/washings were removed, maximal cytoreduction was performed with a goal to reduce the tumor to <1 cm diameter. All patients were given gemcitabine 1250 mg/m2 on day 1 and 8 and cisplatin 70 mg/m2 on day 1 only. Cycles were repeated every three weeks. RECIST was used for response evaluation. Result: One hundred and eight patients were enrolled from December 1998 to December 2013. Median age was 52 years (range 40-68). Seventy two (72) patients had previously received cyclophosphamide and cisplatin while 36 had received paclitaxel and carboplatin. The disease free interval was less than 6 months in 32 patients, more than 6 months in 50 patients and more than 12 months in 26 patients. Optimal cytoreduction was achieved in 42 (38.8%) patient only and included 15, 20 and 7 patients with DFI of <6 months, >6 months and >12 months, respectively. Gut injury was seen in 8 (7.4%) and bladder perforation in 8 (7.4%). Among 42 patients with optimal cytoreduction, 20 had a CR while 22 showed a PR with chemotherapy whereas in patients with sub-optimal surgery CR was seen in 14 patients, PR in 20 and less than PR in 32 patients. Conclusion: Secondary cytoreduction and postoperative second line chemotherapy with Gemcitabine and cisplatin is a reasonable treatment option for patients with recurrent epithelial ovarian cancer. Early cytoreduction seems to confer a favorable surgical outcome. The present data suggests that early detection and surgical intervention of recurrent disease may result in increased response rates. Further studies are needed to validate our findings in larger patient cohorts.
Biography

Nabeela Shami is currently working in the Department of Obstetrics and Gynecology of Lahore Medical & Dental College, Pakistan. She has published many papers in reputed journals.

Email: [email protected]

image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords